Chemed Corporation (CHE): A Bull Case Theory

Core Thesis - Chemed Corporation is viewed positively despite recent stock price declines, with a focus on the recovery potential of its hospice business, VITAS, and the overall valuation dislocation in the market [1][5]. Company Overview - Chemed Corporation operates two distinct businesses: VITAS, a hospice and palliative care provider, and Roto-Rooter, a plumbing services company, generating approximately $2.4 billion in revenue and $370 million in operating income [2]. - The company maintains a strong financial position with a return on invested capital (ROIC) above 20%, return on equity (ROE) in the high 20s, and a net-cash balance sheet [2]. Recent Performance and Market Sentiment - The stock has declined by about one-third recently, with the forward price-to-earnings (P/E) ratio dropping from the mid-20s to around 17x due to a reset in market expectations [3]. - VITAS has faced challenges such as Medicare cap adjustments and management turnover, leading to a significant cut in earnings guidance [3]. Market Outlook - Despite recent setbacks, the hospice market remains attractive due to favorable demographics and Medicare incentives, positioning VITAS for potential revenue growth in the mid- to high-single digits and double-digit operating profit growth in the medium term [3]. - Roto-Rooter is experiencing ongoing challenges from post-COVID normalization and competition, which may limit profitability, but it continues to generate significant cash flow [4]. Valuation Perspective - The current market valuation suggests a pessimistic outlook for VITAS, implying a permanent impairment and minimal future growth potential, which is considered overly negative by analysts [4]. - Chemed's strong free cash flow, disciplined capital returns, and the potential for a valuation rerating as VITAS stabilizes contribute to a favorable risk/reward profile [4].